<DOC>
	<DOCNO>NCT01345916</DOCNO>
	<brief_summary>The purpose study demonstrate CHF 1535 NEXT DPI® non-inferior corresponding dose CHF 1535 pMDI superior market beclomethasone DPI 100 µg term average pre-dose morning Peak Expiratory Flow ( PEF ) asthmatic adult patient .</brief_summary>
	<brief_title>Efficacy CHF1535 Via NEXT DPI Versus pMDI BDP DPI100µg PeakExpiratoryFlow Asthmatic Patients</brief_title>
	<detailed_description>The primary objective demonstrate CHF 1535 NEXT DPI® ( beclomethasone dipropionate + formoterol fumarate 100/6 μg ) , 1 inhalation twice daily , non-inferior correspond dose CHF 1535 pMDI term pulmonary function test ( change baseline entire treatment period average pre-dose morning PEF ) asthmatic adult patient ≥ 18 year treatment fix dose combination Foster® ( beclomethasone dipropionate + formoterol fumarate 100 / 6 μg ) 1 inhalation bid .</detailed_description>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>1 . Male female adult ( ≥18 year old ) . 2 . Reversibility test define ΔFEV1 ≥ 12 % ≥ 200 mL . 3 . FEV1 &gt; 80 % predicted value . 4 . Asthma Control Questionnaire score &lt; 1.25 . 5 . Asthmatic patient 6 . Non exsmokers 1 . History near fatal asthma . 2 . COPD patient 3 . Asthma exacerbation within 1 month prior screen visit asthma exacerbation runin period . 4 . Lower respiratory tract infection within 1 month prior Visit1 ( V1 ) . 5 . History cystic fibrosis , bronchiectasis alpha1 antitrypsin deficiency . 6 . Diagnosis restrictive lung disease . 7 . Patients treat oral parenteral corticosteroid previous 2 month V1 8 . Intolerance contraindication treatment beta 2agonists and/or inhale corticosteroid allergy component study treatment . 9 . Significant medical history and/or treatment 10 . Active cancer history cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>